Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis.

@article{Davenport2009AntibodiesTH,
  title={Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis.},
  author={Andrew Davenport},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={2009},
  volume={54 2},
  pages={
          361-74
        }
}
An 83-year-old man treated with continuous ambulatory eritoneal dialysis for 3 years for end-stage renal disease aused by type 2 diabetes and hypertension was admitted ith peritonitis. After 3 days, there had been no significant mprovement, the peritoneal dialysis catheter was removed, nd he was converted to treatment with intermittent hemodilysis using a right internal jugular catheter. His condition mproved, and after 10 days, he was scheduled to be disharged home after a hemodialysis session… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 93 REFERENCES

Low molecular weight heparin as an lternative anticoagulant to unfractionated heparin for rou- ine outpatient hemodialysis treatments

  • A Davenport
  • Nephrology
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…